InvestorsHub Logo
Followers 5
Posts 437
Boards Moderated 0
Alias Born 01/08/2011

Re: KCAC post# 1023

Wednesday, 07/22/2015 4:55:15 AM

Wednesday, July 22, 2015 4:55:15 AM

Post# of 14939
from your reference:

$6.0M– Imminent Phase II Trial of NK-92 (“aNK”), a special allogeneic, “off-the-shelf” natural killer cell line, to treat merkel cell carcinoma.

they will not make a fortune with that, as merkel cell carcinoma is a rare disease.

any news concerning SBOTF ?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRNE News